Kezar Life Sciences rises as Enodia buys its preclinical assets

Kezar Life Sciences

12/03/2026 13:25

** Shares of Biotech firm Kezar Life Sciences KZR.O rise 2% to $7.16 premarket

** Move comes after private biotech Enodia Therapeutics said it bought Kezar's preclinical drug assets, co says

** Deal includes $1 mln upfront payment and up to $127 mln in future development, regulatory and commercial milestone payments - KZR

** Kezar is also eligible to receive royalties on future sales from the assets, co says

** Co says assets are based on research targeting Sec61, a protein involved in how other proteins are made in the body

** Enodia says the assets could help develop new treatments for inflammation, immune disorders and cancer

** Kezar says the deal allows it to focus resources on advancing its own immune disease programs

** KZR shares down ~6% in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))